Krsnaa Diagnostics Board Approves Q1 FY27 Results, Recommends Final Dividend
Krsnaa Diagnostics approved Q1 FY27 results with consolidated revenue from operations at ₹235.53 crore and profit after tax of ₹65.51 lakh. The company approved issuing 16,21,000 warrants to promoters at a price higher of ₹565 or SEBI floor price. The 16th AGM is scheduled for September 28, 2026, with a record date of September 18, 2026, for a ₹2.00 per share final dividend.
The issuance of warrants to promoters and the declaration of a dividend are material events. The financial results, while approved, do not show exceptionally strong growth, thus leading to a medium impact.
The announcement is positive due to the approval of financial results, the recommendation of a final dividend, and the strategic issuance of warrants to promoters which can strengthen the company's capital structure.
Krsnaa Diagnostics Limited announced the outcome of its Board Meeting held on August 13, 2026. The Board approved the Unaudited (Standalone and Consolidated) Financial Results for the quarter ended June 30, 2026, along with the Limited Review Reports from the statutory auditors.
Additionally, the Board approved the Director's Report, including all annexures, for the financial year 2025-26. The notice for the 16th Annual General Meeting (AGM) was also approved, which is scheduled to be held on Monday, September 28, 2026, at 11:00 Hrs. (IST) in physical mode. The record date for the payment of the final dividend has been set as Friday, September 18, 2026, with book closure from Saturday, September 19, 2026, to Monday, September 28, 2026 (inclusive). The Board recommended a final dividend of ₹2.00 per equity share for the financial year 2024-25.
Furthermore, the company approved the issuance of 16,21,000 share warrants to Mr. Rajendra Mutha and Krsna Diagnostics (Mumbai) Private Limited (Promoter and Promoter Group). The issue price will be determined in the future, at the higher of the floor price as per SEBI (ICDR) Regulations, 2018, or ₹565/-. Each warrant will be convertible into one fully paid-up equity share of face value ₹5/- each, exercisable within 18 months from the allotment date. The Board Meeting commenced at 13:30 Hrs. (IST) and concluded at 21:00 Hrs. (IST).
The financial results for the quarter ended June 30, 2026, show consolidated revenue from operations of ₹235.53 crore and a profit after tax of ₹65.51 lakh. Standalone revenue from operations was ₹210.66 crore with a profit after tax of ₹58.20 lakh.
What to do with a filing like this
Krsnaa Diagnostics Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Krsnaa Diagnostics Limited. Read the original for the full detail.